Overview
Conor McGregor’s ibogaine advocacy refers to the Irish mixed martial artist’s public endorsement of ibogaine after reportedly undergoing treatment at an ibogaine clinic in Tijuana, Mexico.[1][2] Ibogaine is a psychoactive indole alkaloid derived primarily from Tabernanthe iboga, a Central and West African shrub used in traditional ceremonial contexts and later investigated for addiction treatment.[3][4]
McGregor’s comments are significant because celebrity and athlete endorsements can influence public interest, medical tourism, and policy debate around ibogaine and ibogaine therapy.[1][3] However, his reported personal experience is a testimonial rather than clinical evidence, and it should not be treated as proof that ibogaine is safe or effective for TBI, PTSD, addiction, or any other medical condition.[5][6]
Reported Treatment and Public Statements
Media reports state that McGregor underwent ibogaine treatment at Ambio Life Sciences in Tijuana, Mexico, a clinic that has promoted ibogaine services to athletes, veterans, and other clients seeking treatment for trauma, addiction, and neurological symptoms.[1][2] Reports described the experience as lasting about 36 hours and framed the treatment as being aimed at traumatic brain injury, PTSD-like symptoms, anxiety, and depression.[1][2]
McGregor publicly described intense visionary and religious imagery, including a perceived near-death scene and Christian symbolism, and characterized the treatment as life-changing.[1] Independent commentary on the episode cautioned that social-media posts made soon after psychedelic or psychedelic-adjacent experiences can appear psychologically elevated, dysregulated, or difficult to interpret clinically.[7]
Some reports also placed the treatment in a broader period of personal, legal, and professional controversy for McGregor, which complicates interpretation of the advocacy because public therapeutic narratives can overlap with reputation repair, spiritual reframing, or career reinvention.[2][7] Those contextual issues do not prove or disprove therapeutic benefit, but they are relevant when distinguishing a public testimonial from objective clinical data.[1][6]
What Ibogaine Is
Ibogaine is a long-acting psychoactive compound most closely associated with the root bark of Tabernanthe iboga, and it is commonly described as oneirogenic because users often report dream-like visions, autobiographical imagery, and prolonged introspection.[3][4] Its effects differ from classic serotonergic psychedelics such as psilocybin because ibogaine has broad pharmacology across opioid, glutamate, serotonin, dopamine, sigma, and nicotinic acetylcholine systems.[5][8]
After ingestion, ibogaine is metabolized in the liver into noribogaine, a longer-lasting active metabolite that may contribute to anti-craving, mood, and withdrawal-related effects.[4][9] Individual variation in metabolism, including CYP2D6 differences and medication interactions, is one reason medical screening is important before any ibogaine exposure.[8][10]
For a broader primer, see What Is Ibogaine?, Tabernanthe Iboga, and Ibogaine Effects on the Brain.[3][8]
Evidence for Addiction, PTSD, and TBI
The strongest human evidence for ibogaine has historically involved opioid withdrawal and opioid use disorder, where observational studies have reported rapid reductions in withdrawal symptoms and craving after treatment.[9][11] Brown and Alper reported outcomes from 30 people treated for opioid use disorder at clinics in Mexico, finding that many participants experienced acute withdrawal reductions and some reported reduced opioid use during follow-up, although relapse remained common and the study lacked a placebo control.[9]
Noller and colleagues reported a 12-month observational follow-up of people treated for opioid dependence in New Zealand, where some participants reported reduced opioid use and improved functioning after ibogaine treatment.[11] Schenberg and colleagues reported a retrospective Brazilian study of 75 people treated for substance dependence, with self-reported abstinence periods after ibogaine-assisted treatment and longer reported abstinence after repeated sessions, but the study was retrospective and uncontrolled.[4]
The most prominent modern study relevant to McGregor’s stated TBI and trauma context is a 2024 *Nature Medicine* study of U.S. special operations veterans. Special Operations Forces veterans with traumatic brain injury who received ibogaine plus magnesium in Mexico.[5] The study reported large improvements in disability, PTSD symptoms, depression, anxiety, and cognitive measures, but it was open-label, uncontrolled, small, and not sufficient to establish efficacy or broad safety.[5]
For related condition-specific summaries, see Ibogaine for Opioid Addiction, Ibogaine for PTSD, and Ibogaine for TBI.[5][9]
Risks and Safety Concerns
Ibogaine has a more medically concerning safety profile than many better-known psychedelic compounds because it can affect cardiac conduction and prolong the QT interval.[8][10] Laboratory research has shown that ibogaine can inhibit hERG potassium channels, a mechanism associated with drug-induced QT prolongation and potentially life-threatening arrhythmias.[8]
A forensic review by Alper and colleagues examined fatalities temporally associated with ibogaine ingestion and found that many deaths occurred within hours to days of use, often in the presence of cardiovascular disease, seizures, pulmonary embolism, or other substances.[10] The review did not prove that ibogaine alone caused every death, but it reinforced the need for cardiac screening, medication review, electrolyte management, and emergency medical capability.[8][10]
Common acute effects can include nausea, vomiting, ataxia, tremor, light sensitivity, insomnia, dissociation, fear, and intense visionary experiences.[1][3] Psychological risks may be higher in people with bipolar disorder, psychosis vulnerability, severe instability, active suicidality, or inadequate post-treatment integration support.[6][7]
Magnesium was included in the 2024 veteran study as part of a cardiac-safety strategy, but magnesium does not eliminate ibogaine’s intrinsic cardiac risk and should not be interpreted as making unsupervised use safe.[5][8] More detail is available in Ibogaine Side Effects and How to Get Ibogaine Treatment Safely.[6][10]
Legal and Regulatory Status
In the United States, ibogaine is a Schedule I controlled substance under federal law, meaning non-research possession or administration is prohibited outside narrow regulatory pathways. Ibogaine is not approved by the U.S. Food and Drug Administration for addiction, PTSD, traumatic brain injury, depression, anxiety, or any other medical indication.[1][6]
Because ibogaine is illegal or unapproved in many jurisdictions, people seeking treatment often travel to countries where private clinics operate, especially Mexico.[2][3] Medical tourism creates a major quality-control problem because clinic standards can vary widely in screening, ECG monitoring, emergency preparedness, physician involvement, and aftercare.[2][10]
FDA guidance on psychedelic-drug development emphasizes controlled clinical investigations, safety monitoring, and scientifically valid trial design for drugs with psychedelic effects.[6] For legal access context, see Ibogaine Legality by Country, Ibogaine Treatment in Mexico, and Ibogaine Treatment in the United States.[6]
Comparison With Evidence-Based Alternatives
For opioid use disorder, established medications such as methadone, buprenorphine, and extended-release naltrexone have stronger evidence and are part of mainstream addiction-medicine guidance.[12] Ibogaine may have a possible role as an experimental detoxification or anti-craving intervention, but it has not demonstrated the same level of randomized evidence or mortality-reduction evidence as approved medications for opioid use disorder.[9][12]
For PTSD, U.S. Department of Veterans Affairs and Department of Defense guidance emphasizes evidence-based psychotherapies and selected pharmacotherapies rather than ibogaine.[13] Trauma-focused psychotherapies such as prolonged exposure and cognitive processing therapy have a much stronger evidence base than ibogaine for PTSD, while ibogaine research in veterans remains preliminary and uncontrolled.[5][13]
For TBI, there is not yet enough evidence to conclude that ibogaine treats the brain injury itself, even though the 2024 veteran study reported improvements in disability and cognition after treatment.[5] McGregor’s advocacy therefore sits at the intersection of a real scientific signal, high public enthusiasm, and a large evidence-practice gap.[1][5]
Costs, Clinics, and Medical Tourism
Reports about Ambio Life Sciences described tiered programs costing several thousand to tens of thousands of U.S. dollars, including shorter neuroregenerative-style programs, foundation programs, and longer detoxification programs.[2] The same reporting described growth in clinic demand and interest from celebrities, athletes, and military veterans.[2][3]
High cost, exclusivity, ceremonial framing, intensive staff attention, and expectations of transformation can all contribute to placebo and expectancy effects, making uncontrolled testimonials difficult to interpret scientifically.[2][6] These factors do not mean a reported benefit is false, but they do mean that celebrity accounts cannot substitute for randomized trials, standardized outcome measures, and long-term follow-up.[5][9]
People evaluating clinics should focus less on prestige or celebrity associations and more on medical screening, continuous or repeated ECG monitoring, electrolyte correction, medication review, emergency transfer plans, and aftercare.[2][8][10]
Celebrity and Athlete Advocacy
McGregor is part of a broader pattern in which high-profile athletes, veterans, and public figures discuss ibogaine as a potential intervention for addiction, trauma, brain injury, and life transition.[1][3] Reports have also discussed other public figures and athletes who have sought or promoted ibogaine, reflecting a growing link between ibogaine medical tourism and celebrity wellness narratives.[2][3]
Public advocacy may reduce stigma and increase research funding, but it may also encourage people to seek high-risk treatment abroad before the evidence is mature.[5][10] Ethical discussion is especially important when the messenger is polarizing, because public reaction to the celebrity can overshadow the medical evidence, safety issues, and need for regulated trials.[2][7]
Related advocacy pages include Joe Rogan Ibogaine Advocacy, Rick Perry Ibogaine Advocacy, and the homepage Ibogaine.[1][3]
Bottom Line
McGregor’s ibogaine advocacy matters mainly because of his reach as a combat-sports figure and because his reported treatment aligns with rising interest in psychedelic and psychedelic-adjacent interventions for veterans, athletes, trauma, and brain injury.[1][5] The best interpretation is neither dismissal nor uncritical endorsement: ibogaine has credible preliminary evidence, especially for opioid withdrawal and emerging veteran-focused research, but it remains experimental and medically risky.[9][11]
Ibogaine should be approached as a high-risk investigational intervention requiring rigorous screening, cardiac monitoring, emergency readiness, and post-treatment care, not as a wellness supplement or celebrity-proven cure.[8][10] Future acceptance in mainstream medicine would require randomized controlled trials, standardized pharmaceutical manufacturing, clear dosing protocols, long-term follow-up, and a defensible safety framework.[5][6]